Vivacta, a company focused on bringing advanced medical testing closer to patients, has closed a $50.0M Series A funding round. The substantial capital injection signals strong investor confidence in its core technology: piezofilm-based point-of-care diagnostics. This specialized approach involves developing devices that can perform rapid, accurate analyses directly at the point of care, such as a doctor's office or even a patient's home. By moving diagnostic processes out of centralized laboratories and into more accessible settings, Vivacta aims to streamline healthcare delivery and improve patient outcomes through on-the-spot analysis.
Vivacta Raises $50.0M Series
Get the full Vivacta company profile
Access contacts, investors, buying signals & more
From the source
Sci.bio · May 1, 2026This week in biotech continued to reinforce a clear theme across the industry: consolidation is accelerating, and capital is increasingly flowing toward late-stage assets, platform technologies, and revenue-generating structures rather than early discovery-stage innovation.
Ligand Pharmaceuticals agreed to acquire XOMA Royalty in a ~$739M deal, expanding its portfolio of royalty-generating biotech assets and further validating royalty aggregation as a durable investment strategy in the sector: https://loom.ly/WWXsH8Q . Eli Lilly remained highly active on the acquisition front, advancing multiple oncology-focused deals including Kelonia Therapeutics (up to $7B) and A
Other recently funded companies
View all
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
$1.5M Pre-seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Biggest recent Healthcare rounds
Largest funding rounds in Healthcare on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Kismet Australia | Pre-seed | $42.0B | 2y ago |
| 2 |  Johnson & Johnson United States | Unknown | $7.0B |
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
